MY199208A - Benzemesulfonamide compounds and their use as therapeutic agents - Google Patents

Benzemesulfonamide compounds and their use as therapeutic agents

Info

Publication number
MY199208A
MY199208A MYPI2018001969A MYPI2018001969A MY199208A MY 199208 A MY199208 A MY 199208A MY PI2018001969 A MYPI2018001969 A MY PI2018001969A MY PI2018001969 A MYPI2018001969 A MY PI2018001969A MY 199208 A MY199208 A MY 199208A
Authority
MY
Malaysia
Prior art keywords
compounds
benzemesulfonamide
therapeutic agents
withvoltage
odrugs
Prior art date
Application number
MYPI2018001969A
Other languages
English (en)
Inventor
Jean-Christophe Andrez
Christoph Martin Dehnhardt
Thilo Focken
Michael Edward Grimwood
Alla Yurevna Zenova
Kristen Burford
Sultan Chowdhury
Charles Jay Cohen
Robert Joseph Devita
James Roy Empfield
Syed Abid Hasan
James Philip Johnson Jr
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MY199208A publication Critical patent/MY199208A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2018001969A 2016-05-20 2017-05-19 Benzemesulfonamide compounds and their use as therapeutic agents MY199208A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339773P 2016-05-20 2016-05-20
US201662432152P 2016-12-09 2016-12-09
PCT/US2017/033634 WO2017201468A1 (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
MY199208A true MY199208A (en) 2023-10-19

Family

ID=58794232

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001969A MY199208A (en) 2016-05-20 2017-05-19 Benzemesulfonamide compounds and their use as therapeutic agents

Country Status (23)

Country Link
US (4) US10246453B2 (OSRAM)
EP (1) EP3458449B1 (OSRAM)
JP (4) JP6938545B2 (OSRAM)
KR (1) KR102366077B1 (OSRAM)
CN (1) CN109526219B (OSRAM)
AU (2) AU2017268006B2 (OSRAM)
CA (1) CA3023465C (OSRAM)
CL (1) CL2018003260A1 (OSRAM)
CO (1) CO2018012485A2 (OSRAM)
ES (1) ES3022639T3 (OSRAM)
HR (1) HRP20250505T1 (OSRAM)
HU (1) HUE071358T2 (OSRAM)
IL (1) IL262834B (OSRAM)
MX (1) MX386471B (OSRAM)
MY (1) MY199208A (OSRAM)
PH (1) PH12018502378B1 (OSRAM)
PL (1) PL3458449T3 (OSRAM)
RS (1) RS66796B1 (OSRAM)
RU (1) RU2769827C2 (OSRAM)
SG (2) SG11201809702SA (OSRAM)
TN (1) TN2018000385A1 (OSRAM)
WO (1) WO2017201468A1 (OSRAM)
ZA (1) ZA201807518B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246453B2 (en) 2016-05-20 2019-04-02 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2760303C2 (ru) 2016-12-09 2021-11-23 Ксенон Фармасьютикалз Инк. Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
KR102833674B1 (ko) * 2018-06-13 2025-07-14 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
WO2020047312A1 (en) * 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN112638879B (zh) 2018-08-31 2024-06-18 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途
CN115052478A (zh) * 2019-11-21 2022-09-13 犹他大学研究基金会 Trpv4受体配体
EP4228653A4 (en) * 2020-10-13 2024-11-20 Xenon Pharmaceuticals Inc. PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH VOLTAGE-SENSITIVE SODIUM CHANNELS
EP4228654A4 (en) * 2020-10-13 2024-10-16 Xenon Pharmaceuticals Inc. USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER, (S)-4-((1-BENZYLPYRROLIDIN-3-YL))(METHYL) AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL) BENZENESULFONAMIDE, IN CONJUNCTION WITH STRONG CYTOCHROME P450 3A4 INDUCERS, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAV1.6 ACTIVITY
EP4532449A1 (en) 2022-06-02 2025-04-09 Neurocrine Biosciences, Inc. Deuterated compounds
AR133184A1 (es) * 2023-07-07 2025-09-03 Novartis Ag Bloqueadores de canales de sodio
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
WO2025132758A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
CA2288046C (en) 1997-05-07 2006-10-03 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
ES2252996T3 (es) 1999-01-13 2006-05-16 Warner-Lambert Company Llc Derivados de bencenosulfonamida y su uso como inhibidores de mek.
HUP0202180A3 (en) 1999-07-16 2004-10-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2531418A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
CA2539227A1 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
KR20080081178A (ko) 2005-12-21 2008-09-08 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 헤테로사이클릭 유도체
CN101506165B (zh) 2006-08-15 2012-07-04 霍夫曼-拉罗奇有限公司 苯基、吡啶和喹啉衍生物
ATE549336T1 (de) 2006-10-19 2012-03-15 Signal Pharm Llc Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
JP5463285B2 (ja) 2007-07-13 2014-04-09 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
RU2011103451A (ru) 2008-07-01 2012-08-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
PL2385938T3 (pl) 2009-01-12 2015-07-31 Pfizer Ltd Pochodne sulfonamidu
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
CN103119045B (zh) 2010-08-20 2016-02-17 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
RU2014121489A (ru) 2011-10-28 2015-12-10 Мерк Шарп И Доум Корп. Соединения бензоксазолинона с селективной активностью в отношении потенциалзависимых натриевых каналов
ES2586213T3 (es) * 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CN104093716B (zh) * 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
HK1209100A1 (en) * 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
WO2014061970A1 (en) 2012-10-15 2014-04-24 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
KR20150074123A (ko) 2012-10-26 2015-07-01 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 n-치환된 인다졸 술폰아미드 화합물
CA2889378A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
CN105793238B (zh) * 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
WO2015099841A1 (en) 2013-12-23 2015-07-02 Purdue Pharma L.P. Indazoles and use thereof
EP3166939B1 (en) * 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
AU2016370677A1 (en) 2015-12-18 2018-06-07 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US10246453B2 (en) 2016-05-20 2019-04-02 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP3541373B1 (en) 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
RU2760303C2 (ru) 2016-12-09 2021-11-23 Ксенон Фармасьютикалз Инк. Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
KR102833674B1 (ko) * 2018-06-13 2025-07-14 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Also Published As

Publication number Publication date
RU2018145045A3 (OSRAM) 2020-06-22
JP6938545B2 (ja) 2021-09-22
MX2018013985A (es) 2019-08-22
NZ748391A (en) 2025-05-30
EP3458449B1 (en) 2025-03-05
PH12018502378A1 (en) 2019-03-11
JP2025105687A (ja) 2025-07-10
WO2017201468A1 (en) 2017-11-23
ES3022639T3 (en) 2025-05-28
US11299490B2 (en) 2022-04-12
AU2017268006A8 (en) 2018-12-06
US20190194184A1 (en) 2019-06-27
SG10201912216VA (en) 2020-02-27
TN2018000385A1 (en) 2020-06-15
AU2021203771B2 (en) 2022-09-29
AU2017268006A1 (en) 2018-11-22
CA3023465C (en) 2024-09-24
US10662184B2 (en) 2020-05-26
IL262834B (en) 2022-04-01
CN109526219B (zh) 2021-03-12
PH12018502378B1 (en) 2022-08-05
PL3458449T3 (pl) 2025-06-23
US10815229B1 (en) 2020-10-27
CA3023465A1 (en) 2017-11-23
KR102366077B1 (ko) 2022-02-21
EP3458449C0 (en) 2025-03-05
ZA201807518B (en) 2023-07-26
HRP20250505T1 (hr) 2025-06-20
JP2023108032A (ja) 2023-08-03
AU2021203771A1 (en) 2021-07-08
US20200354354A1 (en) 2020-11-12
US20170334902A1 (en) 2017-11-23
MX386471B (es) 2025-03-18
HUE071358T2 (hu) 2025-08-28
SG11201809702SA (en) 2018-12-28
RS66796B1 (sr) 2025-06-30
KR20190007050A (ko) 2019-01-21
AU2017268006B2 (en) 2021-03-11
CL2018003260A1 (es) 2019-01-11
US10246453B2 (en) 2019-04-02
EP3458449A1 (en) 2019-03-27
JP2021185189A (ja) 2021-12-09
BR112018073849A2 (pt) 2019-02-26
JP2019516737A (ja) 2019-06-20
RU2769827C2 (ru) 2022-04-06
IL262834A (en) 2018-12-31
CO2018012485A2 (es) 2019-04-30
CN109526219A (zh) 2019-03-26
RU2018145045A (ru) 2020-06-22

Similar Documents

Publication Publication Date Title
MY199208A (en) Benzemesulfonamide compounds and their use as therapeutic agents
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2018012249A (es) Moduladores de nlpr3.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MY199131A (en) Human plasma kallikrein inhibitors
EA032928B1 (ru) Бициклические кетосульфонамидные соединения
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
EA202190395A1 (ru) Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
SA520420768B1 (ar) مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية
PH12016502246A1 (en) Carboxamide derivatives
PH12022550143A1 (en) Human plasma kallikrein inhibitors
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis
NZ780408A (en) Human plasma kallikrein inhibitors
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека